Vernakalanta efektivitātes un drošuma izvērtējums farmakoloģiskai kardioversijai pacientiem ar īslaicīgas ātriju fibrilācijas paroksismu.
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Darba aktualitāte: ĀF ir visbiežākā no visām aritmijām pasaulē ar nopietnām blakusparādībām. Aktuāli noskaidrot jaunākos līdzekļus farmakoloģiskai kardioversijai.
Darba mērķis: Izvērtēt vernakalanta efektivitāti un drošumu pacientiem ar nesena sākuma ĀF farmakoloģiskajai kardioversijai.
Darba uzdevumi:
1. Sagatavot sistematizētu literatūras apskatu par ĀF farmakoloģisko kardioversiju.
2. Izpētīt un apkopot datus par pieejamajiem vernakalanta efektivitātes pētījumiem paroksismālai nesena sākuma ĀF farmakoloģiskai kardioversijai un noskaidrot vernakalanta efektivitāti, salīdzināt ar citiem medikamentiem un noskaidrot vernakalanta lietošanas drošumu.
Hipotēze: Vernakalants ir efektīvs un drošs farmakoloģiskās kardioversijas līdzeklis pacientiem ar nesena sākuma ĀF.
Pētījuma metodes: Ātrais apskats (angl., Rapid review), tika iekļauti pētījumi no 2004. gada 1. janvāra līdz 2020. gada 27. martam. Pētījumi tika atlasīti atbilstoši iekļaušanas un izslēgšanas kritērijiem. Tika veikta datu analīze, izmantojot MS EXCEL programmatūru.
Rezultāti: Darbā iekļauti 9 pētījumi, no kuriem 6 placebo kontrolēti, bet 3 ar aktīvām kontroles grupām. Vernakalants bija efektīvs 55,28% gadījumu no visiem pētījumiem. Vidējais sīnusa ritma atjaunošanas laiks bija 11,62 minūtes vernakalanta grupās. Biežākās konstatētās blakusparādības bija garšas izmaiņas (13,43%), šķaudīšana (10,23%), hipotensija (9,18%), parestēzijas (8,33%), bradikardija (3,13%) un jebkuri citi ritma traucējumi (4,65%).
Secinājumi: No iegūto pētījumu datiem vernakalants ir efektīvs farmakoloģiskās kardioversijas līdzeklis pacientiem ar īslaicīgu ĀF paroksismu. No pētījumiem, kuros vernakalants tiek salīdzināts ar citiem medikamentiem, kurus izmanto īslaicīgai ĀF paroksisma farmakoloģiskai kardioversijai, var secināt, ka tas ir daudz efektīvāks. Vernakalants sasniedza rezultātu – 71.23% gadījumu, salīdzinājumā ar citiem medikamentiem – 42,07%.
Atslēgas vārdi: vernakalants, ĀF, antiaritmiskie līdzekļi, farmakoloģiskā kardioversija.
Background: Atrial fibrillation is the most common of all arrhythmias in the world with common serious side effects. It was topical to find the latest pharmacological cardioversion agents. Objective: To evaluate the efficacy and safety of vernakalant in recent onset atrial fibrillation patients for pharmacological cardioversion. Tasks: 1. To prepare a systematic literature review on pharmacological cardioversion of atrial fibrillation. 2. To investigate and compile data from available studies on the efficacy of vernakalant for pharmacologic cardioversion of recent onset atrial fibrillation and to determine the efficacy of vernakalant, to compare with other medications, and to determine the safety of vernakalant. Hypothesis: Vernakalant is an effective and safe pharmacological cardioversion agent for patients with recent onset atrial fibrillation. Research Methods: Rapid review, included studies from January 1, 2004 to March 27, 2020. The studies were selected according to inclusion and exclusion criteria. Data was analyzed using MS EXCEL software. Results: The study included 9 studies, of which 6 were placebo-controlled but 3 were active controlled. Vernakalant was effective in 55.28% of all studies. The mean time of the sinus rhythm conversion was 11.62 minutes in the vernakalant groups. The most frequently reported adverse reactions were dysgeusia (13.43%), sneezing (10.23%), hypotension (9.18%), paraesthesia (8.33%), bradycardia (3.13%) and other arrhythmias ( 4.65%). Conclusions: From the data obtained, vernakalant is an effective pharmacological cardioversion agent for patients with recent onset atrial fibrillation. Studies comparing vernakalant with other drugs used for pharmacological cardioversion of recent onset atrial fibrillation show that it is much more effective. Vernakalant achieved an effectivness of 71.23%, compared with 42.07% for other antiarrhytmic agents. Key words: vernakalant, atrial fibrillation, antiarrhythmic agents, pharmacological cardioversion.
Background: Atrial fibrillation is the most common of all arrhythmias in the world with common serious side effects. It was topical to find the latest pharmacological cardioversion agents. Objective: To evaluate the efficacy and safety of vernakalant in recent onset atrial fibrillation patients for pharmacological cardioversion. Tasks: 1. To prepare a systematic literature review on pharmacological cardioversion of atrial fibrillation. 2. To investigate and compile data from available studies on the efficacy of vernakalant for pharmacologic cardioversion of recent onset atrial fibrillation and to determine the efficacy of vernakalant, to compare with other medications, and to determine the safety of vernakalant. Hypothesis: Vernakalant is an effective and safe pharmacological cardioversion agent for patients with recent onset atrial fibrillation. Research Methods: Rapid review, included studies from January 1, 2004 to March 27, 2020. The studies were selected according to inclusion and exclusion criteria. Data was analyzed using MS EXCEL software. Results: The study included 9 studies, of which 6 were placebo-controlled but 3 were active controlled. Vernakalant was effective in 55.28% of all studies. The mean time of the sinus rhythm conversion was 11.62 minutes in the vernakalant groups. The most frequently reported adverse reactions were dysgeusia (13.43%), sneezing (10.23%), hypotension (9.18%), paraesthesia (8.33%), bradycardia (3.13%) and other arrhythmias ( 4.65%). Conclusions: From the data obtained, vernakalant is an effective pharmacological cardioversion agent for patients with recent onset atrial fibrillation. Studies comparing vernakalant with other drugs used for pharmacological cardioversion of recent onset atrial fibrillation show that it is much more effective. Vernakalant achieved an effectivness of 71.23%, compared with 42.07% for other antiarrhytmic agents. Key words: vernakalant, atrial fibrillation, antiarrhythmic agents, pharmacological cardioversion.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
vernakalants, ĀF, antiaritmiskie līdzekļi, farmakoloģiskā kardioversija, vernakalant, atrial fibrillation, antiarrhythmic agents, pharmacological cardioversion.